Literature DB >> 2934431

Neuromyelitis optica: two new cases and review of the literature.

R H Whitham, R L Brey.   

Abstract

The clinical features of two recent cases of neuromyelitis optica are reviewed, along with 43 cases from the literature. Severe bilateral visual impairment, thoracic myelitis, prodromal symptoms suggesting a viral syndrome, and moderate pleocytosis of the cerebrospinal fluid (CSF) were characteristic. Respiratory failure developed in 22% of the cases. Seventy percent of patients improved neurologically, 14% had a poor neurological outcome, and 16% died in the acute stages. Predictors of a poor outcome were older age, marked CSF pleocytosis, and severe myelitis. Forty-two percent of patients had a recurrence of demyelinating disease after initial recovery, suggesting a diagnosis of multiple sclerosis. Fifty-eight percent of patients had a self-limited monophasic illness, consistent with a post-infectious encephalomyelitis. No clear predictors of patients at risk for recurrence were identified. CSF oligoclonal bands were absent in three patients with information available.

Entities:  

Mesh:

Year:  1985        PMID: 2934431

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  3 in total

1.  Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy.

Authors:  H Cock; R Mandler; W Ahmed; A H Schapira
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

2.  Seronegative neuromyelitis optica presenting with life-threatening respiratory failure.

Authors:  Raffaele Nardone; Giulio Zuccoli; Francesco Brigo; Eugen Trinka; Ryan T Fitzgerald
Journal:  J Spinal Cord Med       Date:  2015-12-18       Impact factor: 1.985

3.  Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.

Authors:  Amer Awad; Olaf Stüve
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.